2022 Alpha Mannosidosis Market Growth Analysis, Size, Share, Trends And Forecast

Posted by ramtbrc on January 10th, 2022

LAST WEEK LEFT of our holiday sale! Get your discounted market research reports now.

The Alpha Mannosidosis Global Market Report 2022-31 by The Business Research Company describes and explains the global alpha mannosidosis market and covers 2016 to 2021, termed the historic period, and 2022 to 2026, termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region.

The Alpha Mannosidosis Global Market Opportunities And Strategies Report covers alpha mannosidosis market drivers, alpha mannosidosis market trends, alpha mannosidosis market segments, alpha mannosidosis market growth rate, alpha mannosidosis market major players, and alpha mannosidosis market size.

View more on the Alpha Mannosidosis Market Report:

The alpha mannosidosis market report focuses particularly on identifying the trends, opportunities, and strategies that can lead to success. O&S reports are available off the shelf and can be delivered to clients on the day of purchase.

The Alpha Mannosidosis Global Market Opportunities And Strategies Report is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies in detail. The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market. The chapter also covers markets which have been positively affected by the pandemic.

Request for the report sample:

Alpha Mannosidosis market trends include:
The use of enzyme replacement therapy is increasingly gaining traction in the alpha mannosidosis market. Lamzede (velmanase alfa) is a long-term enzyme replacement therapy in adults, adolescents, and children to help treat mild to moderate forms of alpha-mannosidosis. It is a recombinant human alpha-mannosidase developed as an intravenous enzyme replacement therapy (ERT) to administer the medicine into the bloodstream in order to replace the function of the deficient enzyme in the body. The therapy aims to normalize oligosaccharide levels in the body, which ultimately prevents the progression of the disease and the formation of abnormalities. For instance, as per a study conducted in 2018, the benefits of Lamzede were assessed in 25 patients in a multi-centre, randomized, double-blind, placebo-controlled parallel group trial over 52 weeks showed an improvement in exercise capacity, a decrease of serum oligosaccharide to normal levels, and pulmonary function in certain patients.

The report covers the alpha mannosidosis market segments:
1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Peripheral Blood Stem Cell Transplantation (PBSCT), Gene Therapy
2) By Indication: Type I, Type II, Type III
3) By End-User: Hospitals, Specialty Clinics

About The Business Research Company:
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.

Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Like it? Share it!


About the Author

Joined: July 1st, 2020
Articles Posted: 745

More by this author